光合作用是万物生长的能量源泉，也是光合创投坚持的投资理念：不仅是资源的提供者，更是创新 生态的共建者。作为深耕中国科技赛道的头部基金，光合创投正在通过"光合作用"让科技创新成为 推动社会进步的重要力量。 创业邦将陆续刊载光合创投的投资专栏「光合说」，分享投资背后的故事。 在去年底十四五国家重点研发计划"储能与智能电网技术"重点专项"兆瓦时级液态金属电池中长时储 能技术"项目中，吉兆储能参与了项目中的两个课题。彼时，距离公司成立不到两年。 "作为一家初创公司能有机会参与到国家重点项目中，这对我们无疑是一种肯定，也是一份责任。"吉 兆储能CEO滕鑫表示。 吉兆储能是国内第一家液态金属电池储能系统供应商。去年10月，公司建成了国内首条液态金属电池 10MWh中试产线，涵盖液态金属电池生产、化成、测试、PACK系统、质检等平台，目前已完成了 200Ah级、500Ah级、1000Ah级、2000Ah级等不同规格电芯产品的研发与生产。 "这条产线是全球范围内第一条连续化生产的产线，是团队经过10多年技术的沉淀、积累，向商业化 推进迈出的第一步。"滕鑫强调。 液态金属电池作为一种高效的储能技术，能在可再生能源发电过剩时储存 ...

Group 1: Financing Trends - The technology and manufacturing sectors are the primary focus of capital investment, with significant financing activity observed in semiconductors, robotics, and biomedicine [1][3] - A total of 41 financing events occurred in the domestic primary market from December 8 to December 14, with 34 disclosing amounts totaling approximately 10.36 billion RMB [1][2] Group 2: Sector Highlights - The biomedicine sector completed 7 financing rounds totaling approximately 630 million RMB, while the artificial intelligence sector saw 6 rounds with disclosed amounts around 1.2 billion RMB [3][4] - Notable financing events include Suzhou Saintin Biotech's over 110 million USD B round, and Desheng Medical's 108 million USD B round, indicating strong interest in RNAi therapies and precision oncology [1][11][12] Group 3: Regional Distribution - Financing activities were concentrated in Jiangsu, Shanghai, and Beijing, with 11, 9, and 6 financing events respectively [5][6] Group 4: Active Investment Institutions - Nanshan Zhanxin Investment and Longpan Investment were particularly active, completing 4 and 3 financing rounds respectively, primarily in technology and healthcare sectors [7][8] Group 5: Notable Company Financing - Airwallex, a global cross-border payment platform, completed a 330 million USD G round, achieving a valuation of 8 billion USD [9] - Beijing Tongjia Hongrui Technology raised over 1 billion RMB in a B+ round, focusing on semiconductor materials [20] - Shenzhen New Voice Semiconductor secured nearly 300 million RMB in a C round, emphasizing its leadership in automotive-grade filters [17] - Hangzhou Yundongchu Technology raised over 500 million RMB in a C round, focusing on four-legged and humanoid robots [19]

Group 1: Investment and Financing Activities - Shanghai Zhishi Robotics completed A+ round financing of several tens of millions, exclusively invested by Yinfeng Capital, focusing on four-way shuttle robots for automated storage solutions [2] - Wuhan Jizhao Energy Technology announced the completion of several tens of millions in angel+ round financing led by Guanghe Venture Capital, aimed at supporting the delivery of the world's first MW-level liquid metal battery energy storage system [2] - Deep Intelligent Pharma announced nearly $50 million in D round financing led by Dinghui Baifu, with participation from existing shareholders, to enhance AI-driven drug development [4] - Deshengji Pharmaceutical completed $108 million in B round financing, with investors including IDG Capital and Sequoia China, focusing on precision therapeutic drug development [5] - Skild AI is in negotiations for over $1 billion investment from SoftBank and NVIDIA, potentially increasing its valuation to approximately $14 billion [6] - Pruy Benchmark completed over $10 million in new financing, focusing on AI-driven drug research and development [7] Group 2: Company Developments and Innovations - Zhishi Robotics aims to enhance storage density and efficiency in warehouses through innovative four-way shuttle technology [2] - Jizhao Energy is the first domestic supplier of liquid metal battery energy storage systems, with a pilot production line established for various battery products [2] - Shenzhen Zhaqi Xinzhi focuses on creating a high-throughput, low-cost protein detection platform using semiconductor technology [4] - Skild AI, founded by former Meta AI researchers, aims to develop general AI software systems for robotics, enhancing their perception and decision-making capabilities [6] - Pruy Benchmark leverages multi-omics and AI algorithms to support drug mechanism research and biomarker development [7]